دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Towards a phenotypic understanding of multiple sclerosis depression
Jordyn Anderson and James F Sumowski
doi : 10.1177/13524585221148143
Volume 29 Issue 7, June 2023
Pediatric multiple sclerosis: The 2022 ECTRIMS lecture
Brenda Banwell
doi : 10.1177/13524585231171047
The 2022 ECTRIMS lecture focused on pediatric-onset multiple sclerosis (POMS), in recognition of the pivotal importance of prompt recognition and treatment of children and youth diagnosed with multiple sclerosis (MS), enabled over the past decade by the formal inclusion of pediatric patients in the McDonald diagnostic criteria.
Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis
Gianmarco Abbadessa, Giuseppina Miele, Elisabetta Maida, Emanuele Vanore, Lorenzo Cipriano, Cinzia Coppola, Luigi Lavorgna and Simona Bonavita
doi : 10.1177/13524585221147635
Ocrelizumab is a humanized monoclonal antibody designed to bind to the CD20 molecule, resulting in a rapid depletion of B-cells; however, it has been shown that lymphocyte subpopulations other than B-cells are affected by the drug. To review the effects of ocrelizumab on circulating lymphocytes and identify candidate biomarkers to predict and monitor treatment response.
MS becomes a treatable disease: 30 years later
Fred D Lublin and Stephen C Krieger
doi : 10.1177/13524585231174781
30 years ago the first disease-modifying therapy for relapsing multiple sclerosis was approved for use in the United States and soon thereafter across the globe.
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes
Christine Lebrun-Frenay and Darin T Okuda
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
Ide Smets
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary
Matilde Inglese and Maria Pia Amato
Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS
Vyanka Redenbaugh , Nicholas H Chia, Laura Cacciaguerra, Jennifer A McCombe, Jan-Mendelt Tillema, John J Chen, A Sebastian Lopez Chiriboga , Elia Sechi , Yael Hacohen, Sean J Pittock and Eoin P Flanagan
doi : 10.1177/13524585231166834
Magnetic resonance imaging (MRI) T2-lesions resolve more often in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) than aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and multiple sclerosis (MS) in adults but few studies analyzed children.
Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort
Chen Hu, Blake E Dewey , Ellen M Mowry and Kathryn C Fitzgerald
doi : 10.1177/13524585221148144
Consistent findings on underlying brain features or specific structural atrophy patterns contributing to depression in multiple sclerosis (MS) are limited.
Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)
Martin W Hümmert* , Carlotta Stern* , Friedemann Paul, Ankelien Duchow, Judith Bellmann-Strobl, Ilya Ayzenberg, Carolin Schwake, Ingo Kleiter, Kerstin Hellwig , Sven Jarius, Brigitte Wildemann, Makbule Senel, Achim Berthele, Katrin Giglhuber, Felix Luessi, Matthias Grothe, Luisa Klotz, Rasmus Schülke, Stefan Gingele, Jürgen H Faiss, Annette Walter, Clemens Warnke , Florian Then Bergh, Orhan Aktas, Marius Ringelstein, Jan-Patrick Stellmann, Vivien H?u?ler , Joachim Havla , Hannah Pellkofer, Tania Kümpfel, Bruno Kopp †, Corinna Trebst†; on behalf of the Neuromyelitis Optica Study Group (NEMOS)‡
doi : 10.1177/13524585231151212
There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD).
Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains
Thomas R Valentine , Anna L Kratz, Neeraj Kaplish, Ronald D Chervin and Tiffany J Braley
doi : 10.1177/13524585231169465
Sleep disorders are common in people with multiple sclerosis (PwMS) and could contribute to cognitive dysfunction. However, effects of pathological sleep on cognitive domains are insufficiently characterized.
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis
Ebtesam Alshehri, Jeffrey A Cohen , Daniel Ontaneda , Kunio Nakamura , Scott Husak, Thomas E Love, Robert J Fox , Farren BS Briggs and Devon S Conway
doi : 10.1177/13524585231172490
Smoking is associated with an increased risk of multiple sclerosis (MS) and disability worsening. The relationship between smoking, cognitive processing speed, and brain atrophy remains uncertain.
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs
Rocco Capuano, Luca Prosperini , Manuela Altieri , Lorena Lorefice , Roberta Fantozzi, Paola Cavalla, Clara Guaschino, Marta Radaelli, Cinzia Cordioli, Viviana Nociti, Laura Boffa, Paolo Ragonese, Maria Di Gregorio, Federica Pinardi, Valentina Torri Clerici, Giovanna De Luca, Alberto Gajofatto, Damiano Paolicelli, Carla Tortorella , Claudio Gasperini , Claudio Solaro, Eleonora Cocco , Alvino Bisecco and Antonio Gallo
doi : 10.1177/13524585231167515
Little is known about COVID-19 course and outcomes after a third booster dose of mRNA vaccine against SARS-CoV-2 (mRNA-Vax) in patients with multiple sclerosis (pwMS) treated with ocrelizumab (OCR) and fingolimod (FNG), which showed a weakened immune response to mRNA-vax.
Employment status, productivity loss, and associated factors among people with multiple sclerosis
Elisabet Rodriguez Llorian , Wei Zhang, Amir Khakban, Kristina Michaux, Scott Patten, Anthony Traboulsee, Jiwon Oh, Shannon Kolind, Alexandre Prat, Roger Tam and Larry D Lynd
doi : 10.1177/13524585231164295
Multiple Sclerosis (MS) affects people in their most productive years of life. Consequently, MS can substantially affect employment and work-related outcomes.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Cyrus Daruwalla , Vahid Shaygannejad , Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova , Raed Alroughani , Cavit Boz, Francesco Patti , Marco Onofrj, Alessandra Lugaresi , Sara Eichau , Marc Girard, Alexandre Prat, Pierre Duquette , Bassem Yamout, Samia J Khoury, Seyed Aidin Sajedi , Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt , Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott , Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett , Nevin Shalaby, Marie D’hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara , Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek , Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Trivi?o , Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi , Jiwon Oh , Eduardo Aguera-Morales, Yara Fragoso , Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian , Neil Shuey, Barbara Willekens, Todd A Hardy , Danny Decoo , Angel Perez sempere, Deborah Field, Ray Wynford-Thomas, Nick G Cunniffe, Izanne Roos , Charles B Malpas, Alasdair J Coles, Tomas Kalincik and J William L Brown ; On behalf of the MSBase Study Group
doi : 10.1177/13524585231151951
The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear.
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations
Carolin Otto*, Tatjana Schwarz*, Lara M Jeworowski, Marie L Schmidt , Felix Walper, Florence Pache, Patrick Schindler, Moritz Niederschweiberer, Andi Krumbholz , Ruben Rose , Christian Drosten, Klemens Ruprecht* and Victor M Corman
doi : 10.1177/13524585231161253
To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations.
Leigh syndrome mimicking neuromyelitis optica spectrum disorder (NMOSD)
Nee Na Kim , Omar Abdel-Mannan, James Davidson, Pascale Du Pre, Rachel Kneen, Kshitij Mankad and Yael Hacohen
doi : 10.1177/13524585231172950
We report two children with molecularly confirmed mitochondrial disease mimicking Neuromyelitis Optica Spectrum Disorder (NMOSD). The first patient presented at the age of 15 months with acute deterioration following a pyrexial illness with clinical features localising to the brainstem and spinal cord. The second patient presented at 5 years with acute bilateral visual loss. In both cases, MOG and AQP4 antibodies were negative. Both patients died within a year of symptoms onset from respiratory failure. Arriving at an early genetic diagnosis is important for redirection of care and avoiding potentially harmful immunosuppressant therapies.
Two cases of MT-ND5-related mitochondrial disorder misdiagnosed as seronegative neuromyelitis optica spectrum disorder
Sophie R Wilkins, Amy W Yu, Connolly Steigerwald, Kurenai Tanji, Alejandro D Iglesias, Michio Hirano, Ilya Kister, Claire S Riley and Nicolas J Abreu
doi : 10.1177/13524585231172947
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease primarily affecting the optic nerves and spinal cord, which is usually associated with anti-aquaporin-4 antibodies. Here, we present two individuals who were negative for anti-aquaporin-4 antibodies and were initially diagnosed with seronegative NMOSD.
